Carmichael Hill & Associates, Inc. Vertex Pharmaceuticals Inc Transaction History
Carmichael Hill & Associates, Inc.
- $279 Million
- Q3 2024
A detailed history of Carmichael Hill & Associates, Inc. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Carmichael Hill & Associates, Inc. holds 18 shares of VRTX stock, worth $9,301. This represents 0.0% of its overall portfolio holdings.
Number of Shares
18
Previous 18
-0.0%
Holding current value
$9,301
Previous $8,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding VRTX
# of Institutions
1,717Shares Held
226MCall Options Held
1.19MPut Options Held
1.56M-
Capital World Investors Los Angeles, CA26.7MShares$13.8 Billion2.1% of portfolio
-
Vanguard Group Inc Valley Forge, PA23MShares$11.9 Billion0.21% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$11 Billion0.23% of portfolio
-
State Street Corp Boston, MA11.7MShares$6.06 Billion0.24% of portfolio
-
Capital Research Global Investors Los Angeles, CA8.54MShares$4.41 Billion0.9% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $133B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...